Fluorinov Pharma (Trillium)

trilliumtherapeutics.com
Innovation Type:
Therapeutics
Cancer Type:
Heme
Funding Stage:
Exit
Fund:
Compass Rose
FV162 Oral Proteasome Inhibitor

Related news

    CONNECT WITH FACIT

    Learn more about how we are driving made-in-Ontario oncology innovations reach the market.